NovaBay Pharmaceuticals, Inc. (NBY) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
NBY Revenue Growth
Revenue Breakdown (FY 2024)
NBY's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
NBY Revenue Analysis (2013–2024)
As of May 8, 2026, NovaBay Pharmaceuticals, Inc. (NBY) generated trailing twelve-month (TTM) revenue of $2.8 million, reflecting significant decline in growth of -78.7% year-over-year. The most recent quarter (Q3 2025) recorded $521,000 in revenue.
Looking at the longer-term picture, NBY's 5-year compound annual growth rate (CAGR) stands at +8.2%, indicating steady revenue expansion. The company achieved its highest annual revenue of $18.2 million in 2017.
Revenue diversification analysis shows NBY's business is primarily driven by Total Product Revenue (100%). With over half of revenue concentrated in Total Product Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including AYTU (-3.3% YoY), PRPH (-91.6% YoY), and PCYO (+1.2% YoY), NBY has underperformed the peer group in terms of revenue growth. Compare NBY vs AYTU →
NBY Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| NBYCurrent | $3M | -78.7% | +8.2% | -59.7% | |
 AYTU | $66M | -3.3% | +19.2% | -11.8% | |
 PRPH | $7M | -91.6% | -7.3% | -570.6% | |
 PCYO | $26M | +1.2% | +0.2% | 29.4% |
NBY Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $9.8M | -6.4% | $6.5M | 66.3% | $-5,839,000 | -59.7% |
| 2023 | $10.5M | -27.4% | $6.1M | 58.2% | $-4,102,000 | -39.2% |
| 2022 | $14.4M | +41.2% | $7.8M | 54.0% | $-14,417,000 | -100.1% |
| 2021 | $10.2M | +2.7% | $6.5M | 63.8% | $-8,862,000 | -86.8% |
| 2020 | $9.9M | +50.5% | $6.0M | 60.0% | $-6,426,000 | -64.7% |
| 2019 | $6.6M | -47.2% | $4.9M | 73.7% | $-9,400,000 | -142.4% |
| 2018 | $12.5M | -31.4% | $11.0M | 88.0% | $-7,871,000 | -62.9% |
| 2017 | $18.2M | +53.2% | $15.4M | 84.7% | $-7,311,000 | -40.1% |
| 2016 | $11.9M | +171.6% | $9.4M | 79.3% | $-10,982,000 | -92.3% |
| 2015 | $4.4M | +315.7% | $3.1M | 71.2% | $-21,014,000 | -479.7% |
See NBY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NBY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NBY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNBY — Frequently Asked Questions
Quick answers to the most common questions about buying NBY stock.
Is NBY's revenue growth accelerating or slowing?
NBY revenue declined -78.7% year-over-year, contrasting with the 5-year CAGR of +8.2%. TTM revenue fell to $3M. This reverses the prior growth trend.
What is NBY's long-term revenue growth rate?
NovaBay Pharmaceuticals, Inc.'s 5-year revenue CAGR of +8.2% reflects the variable expansion pattern. Current YoY growth of -78.7% is below this long-term average.
How is NBY's revenue distributed by segment?
NBY reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.